Clinical Trial Update: SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating SGLT2 inhibitors for heart failure with reduced ejection fraction in patients with chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Heart Failure With Reduced Ejection Fraction, Renal Insufficiency, Chronic | Phase 4 | Status: TERMINATED